AnaptysBio, Inc. Common Stock (ANAB) Stock Price

ANABStock

$46.61+103.27%52W

Market Cap$1.39B

P/E10.64x

PEG Ratio—

Div yield—

Beta0.83

ANAB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-10.33%

Price vs S&P 500 (4W)-13.81%

VGM Score58.61

P/E Ratio (Annual)10.64x

P/CF (Annual)77.41x

Book Value / Share (Quarterly)$0.36

P/TBV (Annual)1.45x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)45.68%

Cash Flow / Share (Quarterly)$0.61

Price vs S&P 500 (YTD)32.29%

Net Profit Margin (TTM)82.37%

EPS (TTM)$3.34

10-Day Avg Trading Volume0.52M

EPS Excl Extra (TTM)$3.34

Revenue Growth (5Y)-3.44%

EPS (Annual)$3.50

ROI (Annual)49.05%

Net Profit Margin (5Y Avg)-424.47%

Cash / Share (Quarterly)$5.52

P/E Basic Excl Extra (TTM)7.12x

Revenue Growth QoQ (YoY)23.47%

P/E Normalized (Annual)10.64x

ROA (Last FY)41.33%

Revenue Growth TTM (YoY)92.92%

EBITD / Share (TTM)$3.60

ROE (5Y Avg)152.45%

Operating Margin (TTM)56.36%

Cash Flow / Share (Annual)$-1.77

P/B Ratio131.64x

P/B Ratio (Quarterly)188.81x

Net Income / Employee (Annual)$1,259,600

EV / Revenue (TTM)6.38x

Net Interest Coverage (TTM)-199.47x

ROA (TTM)57.39%

EV / EBITDA (TTM)11.30x

EPS Incl Extra (Annual)$3.50

Current Ratio (Annual)5.61x

Quick Ratio (Quarterly)5.54x

3-Month Avg Trading Volume0.58M

52-Week Price Return103.27%

EV / Free Cash Flow (Annual)78.53x

P/E Incl Extra (TTM)7.12x

Revenue / Employee (TTM)$2,284,700

Tangible BV / Share (Quarterly)$4.53

P/S Ratio (Annual)26.27x

Asset Turnover (Annual)0.17x

52-Week High$72.36

Operating Margin (5Y Avg)-424.38%

EPS Excl Extra (Annual)$3.50

CapEx CAGR (5Y)-31.34%

Tangible BV CAGR (5Y)-3.15%

26-Week Price Return-0.43%

Quick Ratio (Annual)5.54x

13-Week Price Return-19.64%

Total Debt / Equity (Annual)24.23x

Current Ratio (Quarterly)5.61x

Enterprise Value$1.52B

Revenue / Share Growth (5Y)-9.28%

Asset Turnover (TTM)0.70x

Book Value / Share Growth (5Y)-51.24%

Revenue / Employee (Annual)$510,000

Pretax Margin (Annual)-9.60%

Cash / Share (Annual)$5.52

3-Month Return Std Dev49.19%

Net Income / Employee (TTM)$1,882,000

EBITDA Interim CAGR (5Y)7.21%

ROE (Last FY)1237.56%

Net Interest Coverage (Annual)-18.43x

EPS Basic Excl Extra (Annual)$3.50

P/FCF (TTM)14.22x

Receivables Turnover (TTM)6.73x

EV / Free Cash Flow (TTM)83.98x

Total Debt / Equity (Quarterly)24.23x

EPS Incl Extra (TTM)$3.34

Receivables Turnover (Annual)8.96x

ROI (TTM)63.20%

P/S Ratio (TTM)5.86x

Pretax Margin (5Y Avg)-475.74%

Revenue / Share (Annual)$1.42

Tangible BV / Share (Annual)$9.19

Forward P/E49.51x

Price vs S&P 500 (52W)87.74%

P/E Ratio (TTM)7.12x

Year-to-Date Return44.21%

5-Day Price Return1.24%

EPS Normalized (Annual)$3.50

ROA (5Y Avg)-9.92%

Net Profit Margin (Annual)246.96%

Month-to-Date Return-7.26%

Cash Flow / Share (TTM)$-5.37

EBITD / Share (Annual)$0.86

Operating Margin (Annual)60.93%

LT Debt / Equity (Annual)24.23x

P/CF (TTM)77.06x

ROI (5Y Avg)-15.91%

P/E Excl Extra (TTM)7.12x

LT Debt / Equity (Quarterly)24.23x

EPS Basic Excl Extra (TTM)$3.34

P/TBV (Quarterly)3.15x

P/B Ratio (Annual)188.81x

Pretax Margin (TTM)25.13%

Book Value / Share (Annual)$0.36

Price vs S&P 500 (13W)-22.32%

Beta0.83x

P/FCF (Annual)71.06x

Revenue / Share (TTM)$3.72

ROE (TTM)894.97%

52-Week Low$20.18

vGradeC

gGradeC

mGradeB

vgmGradeC

ANAB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Sep 21, 2026	$0.14	$4.93	+3384.35%(+$4.79)
Q4 2025	Mar 3, 2026	$0.93	$1.58	+69.26%(+$0.65)
Q3 2025	Nov 4, 2025	-$1.25	$0.52	+141.58%(+$1.77)
Q2 2025	Aug 6, 2025	-$1.58	-$1.34	+15.27%(+$0.24)

ANAB Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ANABAnaptysBio, Inc. Common Stock	C	C	B	5.9x	92.9%	—	—	$46.61
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About AnaptysBio, Inc. Common Stock

AnaptysBio Inc develops immune cell-modulating antibody therapies for inflammatory and autoimmune diseases. The company's lead program, rosnilimab, a PD-1 agonist, is in Phase 2b trials for rheumatoid arthritis and Phase 2 trials for ulcerative colitis. It is also developing ANB032, a BTLA agonist in Phase 2b testing for atopic dermatitis.